p53 in hematologic malignancies

Blood

Volumn 84, Issue 8, 1994, Pages 2412-2421

  Imamura, Jun ^b   Miyoshi, Isao ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BURKITT LYMPHOMA; CHROMOSOME LOSS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DNA POLYMORPHISM; FAMILIAL CANCER; GENE MUTATION; GENE THERAPY; HEMATOLOGIC DISEASE; HETEROZYGOSITY; HODGKIN DISEASE; HUMAN; IMMUNOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; T CELL LEUKEMIA; TUMOR SUPPRESSOR GENE;

EID: 0027942844     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v84.8.2412.2412     Document Type: Review

References (155)

1. Culotta E, Koshland DE Jr: p53 Sweeps through cancer research. Science 262:1958, 1993
2. Lane DP, Crawford LV: T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261, 1979
3. Linzer DIH, Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43, 1979
4. Eliyahu D, Michalowitz D, Oren M: Overproduction of p53 antigen makes established cells highly tumorigenic. Nature 316:158, 1985
5. Parada LF, Land H, Weinberg RA. Wolf D, Rotter V: Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 312:649, 1984
6. Rovinski B, Benchimol S: Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2:445, 1988
7. Lane DP, Benchimol S: P53: Oncogene or anti-oncogene? Genes Dev 4:1, 1990
8. Montenarh M: Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7:1673, 1992
9. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523, 1992
10. Tuck SP, Crawford L: Overexpression of normal human p53 in established ribroblasts leads to their tumorigenic conversion. Oncogene Res 4:81, 1989
11. Eliyahu D, Raz A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 312:646, 1984
12. Jenkins JR, Rudge K, Currie GA: Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature 312:651, 1984
13. Finlay CA, Hinds PW, Levine AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083, 1989
14. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763, 1989
15. Hinds P, Finlay K, Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739, 1989
16. Chen P-L, Chen YM, Bookstein R, Lee W-H: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576, 1990
17. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453, 1991
18. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531, 1988
19. Wolf D, Rotter V: Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82:790, 1985
20. Mowat M, Cheng AM, Kimura N, Bernstein A, Benchimol S: Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature 314:633, 1985
21. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ: Rearrangement of the p53 gene is common in human osteogenic sarcoma. Proc Natl Acad Sci USA 84:7716, 1987
22. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R: Allelotype of colorectal carcinomas. Science 244:207, 1989
23. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491, 1989
24. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705, 1989
25. Miller CW, Aslo K, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950, 1990
26. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler HP: p53 mutations in human lung tumors. Cancer Res 52:1695, 1992
27. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutation in human lymphoid malignancies associated with Burkit lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
28. Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87:9958, 1990
29. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427, 1991
30. Sidransky D, Voneschenbacj A, Tsai YC, Jones P, Summerhayes F, Marshall I, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706, 1991
31. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP: Mutations of the p53 gene in adult T-cell leukemia. Blood 70:477, 1992
32. Fagin JA, Matsuo K, Karmakar A, Chen D-L, Tang SH, Koeffler HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179, 1993
33. Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H, Koeffler HP: Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53:4053, 1993
34. Sugito S, Yamato K, Sameshima Y, Yokota J, Yano S, Miyoshi I: Adult T-cell leukemia: Structures and expression of the p53 gene. Int J Cancer 49:880, 1991
35. Nagai H, Kinoshita T, Imamura J, Murakami Y, Hayashi K, Mukai K, Ikeda S, Tobinai K, Saito H, Shimoyama M: Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 82:1421, 1991
36. Ichikawa A, Hotta T, Takagi N, Tsushita K, Kinoshita T, Nagai H, Murakami Y, Hayashi K, Saito H: Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 79:2701, 1992
37. Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ: Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86:6783, 1989
38. Foti A, Bar-Eli M, Ahuja HG, Cline MJ: A splicing mutation accounts for the lack of p53 gene expression in a CML blast crisis cell line: A novel mechanism of p53 gene inactivation. Br J Haematol 76:143, 1990
39. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87:2042, 1991
40. Foti A, Ahuja HG, Alien SL, Koduru P, Schuster MW, Schulman P, Bar-Eli M, Cline MJ: Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 77:2441, 1991
41. Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V: Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74:2318, 1989
42. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H: Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022, 1993
43. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K. Hirai H, Ishikawa F, Takaku F: Mutations of the p53 gene in lymphoid leukemia. Blood 77:1153, 1991
44. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y, Hirai H: Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79:2378, 1992
45. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491, 1992
46. Kastan MB, Zhan QM, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587, 1992
47. Ponder B: Gene losses in human tumours. Nature 335:400, 1988
48. Harris N, Brill E, Shohat O, Prokocimer M, Arai N, Wolf D, Rotter V: Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol 6:4650, 1986
49. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766, 1989
50. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874, 1989
51. Suzuki Y, Orita M, Shiraishi M, Hayashi K, Sekiya T: Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 5:1037, 1990
52. Murakami Y, Hayashi K, Sekiya T: Detection of aberrations of p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res 51:3356, 1991
53. Hayashi K: PCR-SSCP: A simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Applications 1:34, 1991
54. Paquette RL, Karmakar A, Kizaki M, Wilcynzski SP, Miller CW, Koeffler HP: Mutations of p53 and human papillomavirus infection occur independently in cervical carcinoma. Cancer 72:1272, 1993
55. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49, 1991
56. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945, 1990
57. Vogelstein B: A deadly inheritance: Nature 348:681, 1990
58. Borresen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend S: Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88:8405, 1991
59. Gibbs R, Caskey CT: Identification and localization of mutations at the Lesch-Myhan locus by ribonuclease A cleavage. Science 236:303, 1987
60. Fischer SG, Lerman LS: DNA gragments differing by single base-pair substitutions are separated in denaturing gradient gels: Correspondence with melting theory. Proc Natl Acad Sci USA 80:1579, 1983
61. Sheffield VC, Cox DR, Lerman LS, Myers RM: Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci USA 86:232, 1989
62. Cotton RGH, Rodreques NR, Campbell RD: Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci USA 85:4397, 1988
63. Iggo R, Gatter K, Bãrtek J, Lane D, Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675, 1990
64. Gusterson BA, Anbazhagan R, Warren W, Midgley C, Lane DP, O'Hare M, Stamps A, Carter R, Jayatilake H: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6:1785, 1991
65. Cossman J, Schlegel R: p53 in the diagnosis of human neoplasia. J Natl Cancer Inst 83:980, 1991
66. Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A: Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75:180, 1990
67. Gupta RK, Norton AJ, Thompson IW, Lister TA, Bodmer JG: p53 expression in Reed-Sternberg cells of Hodgkin's disease. Leuk Suppl 2:S31, 1993
68. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M: Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol 5:67, 1991
69. Niedobitek G, Rowlands DC, Young LS, Herbst H, Williams A, Hall P, Padfield J, Rooney N, Jones L: Overexpression of p53 in Hodgkin's disease: Lack of correlation with Epstein-Barr virus infection. J Pathol 169:207, 1993
70. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P: P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166:235, 1992
71. Nakamura H, Said JW, Miller CW, Koeffler HP: Mutation and protein expression of p53 in acquired immunodeficiency syndromerelated lymphomas. Blood 82:920, 1993
72. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1592, 1990
73. Lubbert M, Miller CW, Crawford L, Koeffler HP: P53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J Exp Med 167:873, 1988
74. Nakai H, Misawa S, Toguchida J, Yandel DW, Ishizaki K: Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52:6588, 1992
75. Feinstein E, Gale RP, Reed J, Canaani E: Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene 7:1853, 1992
76. Koeffler HP, Miller C, Nicolson MA, Ranyard J, Bosselman RA: Increased expression of p53 protein in human leukemia cells. Proc Natl Acad Sci USA 83:4035, 1986
77. Smith LJ, McCulloch EA, Benchimol S, Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med 164:751, 1986
78. Prokocimer M, Shaklai M, Bassat HB, Wolf D, Goldfinger N, Rotter V: Expression of p53 in human leukemia and lymphoma. Blood 68:113, 1986
79. Slingerland JM, Minden MD, Benchimol S: Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77:1500, 1991
80. Fenaux P, Jonveaux P, Quiquandon I, Laï JL, Pignon JM, Loucheux-Lefebvre MH, Bauters F, Kerckaert JP: P53 gene mutations in myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
81. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in acute myeloid leukaemia. Br J Haematol 80:178, 1992
82. Wada M, Bartram CR, Nakamura H, Hachiya M, Chen DL, Borenstein J, Hansen-Hagge TE, Ludwig WD, Reiter A, Mizoguchi H, Koeffler HP. Analysis of p53 mutations in large series of lymphoid hematological malignancies of childhood. Blood 82:3163, 1993
83. Preudhomme C, Quesnel B, Vachee A, Lepelley P, Collyn-D'Hooghe M, Wattel E, Fenaux P: Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia 7:1291, 1993
84. Jonveaux PH, Fenaux P, Quiquandon I, Pignon JM, Lai JL, Loucheux-Lefebvre MH, Goossens M, Bauters F, Berger R: Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243, 1991
85. Zhang W, Hu Guiying, Estey E, Hester J, Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 7:1645, 1992
86. Rivas CI, Wisntewski D, Strife A, Perez A, Lambek C, Bruno S, Darzynkiewicz Z, Clarkson B: Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood 79:1982, 1992
87. Milner J, Medcalf EA: Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765, 1991
88. Milner J: Different forms of p53 detected by monoclonal antibodies in non-dividing and dividing lymphocytes. Nature 310:143, 1984
89. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M: The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617, 1993
90. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell Mol Genet 13:235, 1987
91. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565, 1991
92. Barak Y, Oren M: Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J 11:2115, 1992
93. Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 69:1237, 1992
94. Finlay CA: The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13:301, 1993
95. Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild type p53 activity. EMBO J 12:461, 1993
96. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855, 1993
97. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80, 1992
98. Yonish G, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345, 1993
99. Low Sw, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
100. Clark AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wylie AH: Thyomocyte apoptosis induced by p53-dependent and independent pathways. Nature 363:849, 1993
101. Fenaux P, Jonveaux P, Quiquandon I, Preudhomme C, Lai JL, Vanrumbeke M, Loucheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: A report on 60 cases. Leukemia 6:42, 1992
102. Felix CA, Nau MM, Takasashi T, Mitsudomi T, Chiba I, Poplak DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T, Minna JD: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89:640, 1992
103. Cheng J, Haas M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502, 1990
104. Norley Sg, Kurth R: Retroviruses and malignant lymphoma. Blut 58:221, 1989
105. Seiki M, Hattori S, Hirayama Y, Yoshida M: Human adult T-cell leukemia virus: Complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA 80:3618, 1983
106. Sodroski J, Rosen C, Goh WC, Haseltine W: A transcriptional activator protein enccoded by the x-lor region of the human T-cell leukemia virus. Science 228:1430, 1985
107. Lübbert M, Miller CW, Kahan J, Koeffler HP: Expression, methylation and chromatin structure of the p53 gene in untransformed and human T-cell leukemia virus type I-transformed human T-lymphocytes. Oncogene 4:643, 1989
108. Said JW, Barrera R, Shinataku IP, Nakamura H, Koeffler HP: Immunohistochemical analysis of p53 expression in malignant lymphomas. J Pathol 141:1343, 1992
109. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M: Immunohistochemical evidence for abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol Pathol 5:67, 1991
110. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, Martinez JC, Martinez P: p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 166:235, 1992
111. Gupta RK, Patel K, Bodmer WF, Bodmer JG: Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc Natl Acad Sci USA 90:2817, 1993
112. Trumper LH, Brady G, Bagg A, Gray D, Loke SL, Griesser H, Wagman R, Braziel R, Gascoyne RD, Vicini S, Iscove NN, Cossmann J, Mak TW: Single-cell analysis of Hodgkin and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p53 mutations'. Blood 81:3097, 1993
113. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RSK, Dalla-Favera R: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289, 1993
114. Farrugia M, Duan LJ, Reis MD, Ngan BY, Berinstein NL: Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-myc and BCL-2 proto-oncogenes. Blood 83:191, 1994
115. Rodriquez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth AB: Chromosome 17- and p53 changes in lymphoma. Br J Haematol 79:575, 1991
116. Ballerini P, Gaidano G, Gong JZ, Tassi V, Saglio G, Knowles DM, Dalla-Favera R: Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 81:166, 1993
117. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in CD30 (Ki-1) positive anaplastic large cell lymphoma. Modern Pathol 6:87A, 1993
118. Matsushima A, Cesarman A, Chadburn A, Liu J, Knowles DM: p53 protein overexpression frequently occurs but p53 gene mutations infrequently occur in post thymic T cell lymphomas. Modern Pathol 6:95A, 1993
119. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
120. Farrell PJ, Allan GJ, Shanahan F, Vousden KH, Crook T: p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 10:2879, 1991
121. Wiman KG, Magnusson KP, Ramqvist T, Klein G: Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633, 1991
122. Vousden KH, Crook T, Farrell PJ: Biological activities of p53 mutants in Burkitt's Iymphoma cells. J General Virol 74:803, 1993
123. Bhatia KS, Gutie'rrez MI, Huppi K, Siwarski D, Magrath IT: The pattern of p53 mutations in Burkitt's Iymphoma differs from that of solid tumors. Cancer Res 52:4273, 1992
124. Mannick JB, Cohen JI, Birkenbach M, Marchini A, Kieff E: The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol 65:6826, 1991
125. Effert P, McCoy R, Abdel-Hamid M, Flynn K, Zhang Q, Busson P, Tursz T, Liu E, Raab-Traub N: Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 66:3768, 1992
126. Spruck Ch, Tsai YC, Huang DP, Yang AS, Rideout WM III, Gonzales-Zulueta M, Choi P, Lo K-W, Yu MC, Jones PA: Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 52:4787, 1992
127. Preudhomme C, Facon T, Zandecki M, Vantumbeke M, Lai JL, Nataf E, Loucheux-Lefebvre MH, Kerckaert JP, Fenaux P: Rare occurrence of p53 gene mutations in multiple myeloma. Br J Haematol 81:440, 1992
128. Portier M, Moles JP, Mazars GR, Jeanteur Ph., Bataille R, Klein B, Theillet Ch: p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539, 1992
129. Ner A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128, 1993
130. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet Ch, Klein B: Mutations of the p53 gene in human myeloma cell lines. Oncogen 7:1015, 1992
131. Palumbo AP, Pileri A, Dianzani U, Massaia M, Boccadoro M, Calabretta B: Altered expression of growth-regulated protooncogenes in human malignant plasma cells. Cancer Res 49:4701, 1989
132. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakemura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217, 1989
133. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846, 1992
134. Fults D, Brockmeyer D, Tullous MW, Pedone CA. Cawthon RM: p53 mutations and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 52:674, 1992
135. Shirasawa S, Urabe K, Yanagawa Y, Toshitani K, Iwama T, Sasazuki T: p53 gene mutations in colorectal tumors from patients with familial polyposis coli. Cancer Res 51:2874, 1991
136. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF, Li FP: Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res 51:6094, 1991
137. Malkin D, Li FP, Strong LC, Graumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233, 1990
138. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747, 1990
139. Li FP, Prraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:558, 1988
140. Li FP, Correa P, Fraumeni JF: Testing for germ line p53 mutations in cancer families. Cancer Epidemiol Biomarkers Prev 1:91, 1991
141. Toguchida J, Yamaguchi T, Herrera G, Beauchamp R, Yandell DW: A survey of germ-line and somatic p53 gene mutations in patients with bone and soft tissue sarcomas. Am J Hum Genet 49:(S)458, 1991
142. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Anderson TI, Borrensen A-L, Li FB, Garber J, Strong LC: Gennline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309, 1992
143. Felix CA, D'Amico D, Mitsudomi T, Nau MM, Li FP, Fraumeni JP Jr, Cole DE, McCalla J, Reaman GH, Whang-Peng J: Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest 90:653, 1992
144. Frebourg T, Friend SH: Cancer risks from germline p53 mutations. J Clin Invest 90:1637, 1992
145. Li FP, Garber JE, Friend SH, Strong LC, Patenaude AF, Juengst ET, Reilly PR, Correa P, Fraumeni JF: Recommendations on predictive testing for germline p53 mutations among cancer-prone individuals. J Nat Cancer Inst 84:1156, 1992
146. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912, 1990
147. Diller L, Kassel J, Nelson C, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772, 1990
148. Johnson P, Gray D, Mowat M, Benchimol S: Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 11:1, 1991
149. Friedmann T: Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 70:1810, 1992
150. Fujiwara T, Grinmm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129, 1993
151. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP: Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res 54:1175, 1994
152. + cytotoxic T-cells. Cancer Res 53:3257, 1993
153. Caron de Fromentel C., May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P: Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 39:185, 1987
154. Crowford LV, Pim DC, Bulbrook RD: Detection of antibodies against the host protein p53 in sera from patients with breast cancer. Int J Cancer 30:403, 1982
155. Winter Sf, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of mutation. Cancer Res 52:4168, 1992